eHealth, Inc. (EHTH) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed results: a decline in revenue and net loss, but improved gross margins and cost reductions. The Q&A highlights management's focus on long-term strategies and confidence in meeting future guidance, despite current challenges. The lack of detailed guidance on new models and the unclear impact of tail revenue limit positive sentiment. With no market cap data, a neutral outlook is appropriate, balancing short-term challenges with potential long-term gains.
Key Financial Performance
First Quarter Revenue $88 million, representing a 22% decline year-over-year. The decline was primarily driven by lower enrollment volume as the company reduced variable marketing spend to focus on best-performing channels.
Medicare Segment Revenue $81.3 million, a 22% decline year-over-year. This was driven by a 24% decline in Medicare submissions, partially offset by growth in lifetime values for Medicare Advantage, Medicare Supplement, and PDP products.
Non-Commission Revenue $8.2 million, reflecting lower carrier sponsorship revenue compared to a year ago.
Medicare LTV to CAC Ratio 1.4x, representing a 17% improvement from 1.2x year-over-year. This improvement was driven by a 28% reduction in variable marketing cost per MA equivalent approved member and improved channel mix.
First Quarter Lifetime Values Increased 3% for Medicare Advantage, 19% for Medicare Supplement, and 78% for PDP products year-over-year.
Medicare Segment Gross Profit $33 million, down 8% year-over-year. However, gross profit margin increased from 34% to 41%, reflecting improvements in the Medicare LTV to CAC ratio.
Employer and Individual Segment Revenue $6.7 million, down 29% year-over-year. Segment gross profit was $3.7 million compared to $6 million last year.
GAAP Net Loss $4.7 million compared to GAAP net income of $2 million in the prior year. The decline was primarily driven by restructuring charges related to headcount reduction.
Adjusted EBITDA $9 million, down from $12.5 million year-over-year. Adjusted EBITDA margin was 10% compared to 11% in the prior year.
Non-GAAP Total Operating Expenses Declined 21% to $82.3 million year-over-year, reflecting organization-wide expense reductions.
Operating Cash Flow $35.8 million compared to $77.1 million year-over-year. The decline was due to timing of working capital items and severance costs associated with fixed cost reduction actions.
Cash, Cash Equivalents, and Short-Term Marketable Securities $110.8 million as of March 2026.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Lifetime Advisory Model: eHealth launched a lifetime advisory model to foster deeper relationships with members, supported by new agent-facing technology tools for personalized and proactive engagement.
Final Expense Insurance: Introduced final expense insurance products, offering financial protection and attractive unit economics. Plans to expand product offerings based on consumer focus groups and industry research.
Medicare Advantage Market: CMS finalized the 2027 Medicare Advantage rate above initial proposals, signaling responsiveness to industry feedback. Carriers are developing 2027 bids, with a focus on margin and adjustments to benefits and service areas.
Cost Reductions: Implemented headcount reductions and vendor consolidation, reducing fixed operating costs by approximately $30 million in 2026 compared to 2025.
Operational Efficiency: First quarter Medicare LTV to CAC ratio improved by 17%, and total acquisition cost per MA equivalent approved member declined by 10%.
Revenue Growth Strategy: Focused on achieving breakeven or better operating cash flow in 2026, with plans for mid-single-digit revenue growth in 2027 and mid-teens growth in 2028.
Diversification Initiatives: Expanding ancillary product offerings and launching ICHRA business to complement core Medicare commission revenue.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Medicare Advantage reset cycle: The ongoing Medicare Advantage reset cycle is causing adjustments to planned benefits, service areas, and plan eliminations, leading to complex carrier inventory dynamics and potential challenges in consumer demand and carrier strategies.
Cost reductions and restructuring: The company implemented headcount reductions and vendor consolidation initiatives, which, while reducing fixed operating costs, may impact operational efficiency and employee morale in the short term.
Variable marketing and agent-related spend: The strategic decision to reduce variable marketing and agent-related spend could limit enrollment volume and market reach, potentially affecting revenue growth in the short term.
Revenue decline in Employer and Individual segment: Revenue in the Employer and Individual segment declined by 29%, indicating challenges in this business area that could impact overall financial performance.
Lower carrier sponsorship revenue: A decline in carrier sponsorship revenue compared to the previous year could affect non-commission revenue streams and overall financial stability.
Restructuring charges: Restructuring charges related to headcount reductions contributed to a GAAP net loss, highlighting financial strain from organizational changes.
Economic uncertainties in Medicare market: The Medicare market's stabilization timeline remains uncertain, which could impact revenue growth and strategic planning.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Medicare Advantage Market Outlook: CMS finalized the 2027 Medicare Advantage rate above the initial proposal, signaling responsiveness to industry feedback and long-term program sustainability. Carriers are developing 2027 bids, with a focus on margin rather than market share, leading to adjustments in benefits, service areas, and plan eliminations. Consumer demand is expected to remain strong, with complex carrier inventory dynamics.
Lifetime Advisory Model: The company is evolving its operating model to foster deeper, longer-lasting relationships with members. This includes the rollout of a lifetime advisory model supported by new agent-facing technology tools, customer dashboards, and system-generated recommendations. The model aims to improve retention, increase member lifetime value, and enable effective cross-selling.
Revenue Growth Projections: The company expects mid-single-digit revenue growth in 2027, increasing to mid-teens in 2028. Growth will be driven by core Medicare Advantage business, ancillary sales, and contributions from the Employer and Individual (E&I) segment starting in 2028.
Adjusted EBITDA Margin Expansion: Adjusted EBITDA margins are expected to increase each year starting in 2027, reaching 20% by 2028. This reflects benefits from fixed cost reductions and favorable Medicare unit economics.
Free Cash Flow Goals: The company forecasts achieving breakeven or better free cash flow in 2027.
2026 Financial Strategy: 2026 is positioned as a bridge year, focusing on improving revenue quality, enhancing operating efficiency, and achieving cash flow generation rather than maximizing volume. The company is maintaining its 2026 guidance ranges for revenue, GAAP net income, adjusted EBITDA, and operating cash flow.
Product and Service Expansion: The company launched final expense insurance offerings in April 2026 and plans to add more products and services based on consumer focus groups and industry research. These initiatives aim to enrich inventory, provide financial protection, and enhance cash flow profiles.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Do you have any tail revenue embedded in your revenue growth targets, and how would realizing tail revenue this year affect your growth rate?
A:The company assumes flat tail revenue growth in its long-range plan, consistent with 2026 guidance. Realizing tail revenue within the guidance range would not lower the expected EBITDA growth rate for 2027. However, significant positive developments beyond current guidance could impact growth rates.
Q:Why was cash flow in the first quarter below last year's number, and how confident are you in achieving full-year cash flow guidance?
A:About 80% of the decline was due to lower carrier sponsorship timing, severance costs related to fixed cost reductions, and lower commission collections from reduced volume. Despite this, cash flow exceeded expectations, and the company is on track to achieve 2026 guidance ranges.
Q:What are the differences in your approach to growth and marketing in 2026 compared to 2025?
A:The focus in 2026 is on generating positive operating cash flow and strengthening the company's foundation. This includes disciplined marketing, pulling back from less profitable channels, and implementing a lifetime advisory model to improve retention and ancillary sales. The approach builds on strategies initiated in 2025 but emphasizes long-term relationships and profitability.
Q:What is the Lifetime Advisory model, and how does it change engagement with customers?
A:The Lifetime Advisory model encourages advisers to develop holistic relationships with members, acting as a one-stop shop for their needs. It focuses on cultivating long-term relationships, improving retention, and cross-selling ancillary products without additional marketing spend or agents. Engagement activities include follow-ups, wellness visits, and referrals.
Q:What percentage of Medicare enrollment mix in Q1 came from branded marketing channels, and how does it compare to last year?
A:The company continues to lean into branded channels, optimizing marketing spend based on quality and return metrics like LTV to CAC. The mix of branded channels has improved and is expected to continue improving into Q4.
Q:What are the unit economics of cross-selling ancillary products through the Lifetime Advisory model and ICHRA, and how do these products impact the company's margin profile and revenue growth?
A:Cross-selling ancillary products can add 15%-20% to the LTV of an MA sale. Ancillary products have a favorable cash flow profile. ICHRA is currently a small part of the revenue growth plan and not material to the 2028 revenue growth projections.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the unit economics of ICHRA, stating it is too early to share such information. Additionally, while they discussed the Lifetime Advisory model and its benefits, they did not provide precise metrics or data on its expected impact on revenue growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AEP
Advantage reset
CMS
Chief
Dolan
Medicare Advantage
Medicare enrollment
Officer
adviser
afternoon today
agent
beneficiary
bid
carrier
channel
consumer
core
cost reduction
coverage
decision
digit percentage
diversification
eHealth
economics cash
enrollment volume
expense insurance
filing SEC
health
inventory
lifetime model
offering
progress
reset cycle
sale
system
tool
unit economics
EHTH Transcript
eHealth, Inc. (EHTH) Q1 2026 Earnings Call Transcript
Unknown5-7
The earnings call reveals mixed results: a decline in revenue and net loss, but improved gross margins and cost reductions. The Q&A highlights management's focus on long-term strategies and confidence in meeting future guidance, despite current challenges. The lack of detailed guidance on new models and the unclear impact of tail revenue limit positive sentiment. With no market cap data, a neutral outlook is appropriate, balancing short-term challenges with potential long-term gains.
MDA Space Ltd. (MDA:CA) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call reveals positive elements such as increased revenue and net income guidance for 2025, a strong pipeline with potential conversions, and strategic investments in chip capabilities. Despite some uncertainties in defense margins and unclear responses, the overall sentiment is optimistic with expected significant contributions from defense by 2027 and a focus on technological leadership. The positive guidance adjustments and strategic growth initiatives indicate a likely positive stock price movement in the short term.
eHealth, Inc. (EHTH) Q4 2025 Earnings Call Transcript
Positive3-4
The earnings call highlights strong financial performance, with significant growth in GAAP net income, adjusted EBITDA, and sales. Despite a softer revenue outlook for 2026, the focus on high-margin channels and operational efficiency is promising. The Q&A section reveals proactive strategies to enhance margins and a positive outlook for 2027. These factors, combined with a record high revenue and improved guidance, suggest a positive stock price movement over the next two weeks.
eHealth, Inc. (EHTH) Q3 2025 Earnings Call Transcript
Unknown11-6
The earnings call presents a mixed outlook. Positive elements include improved guidance for revenue and net income, and optimistic long-term Medicare Advantage growth. However, the current financials show declining revenue and significant losses, with unclear management responses raising concerns. The Q&A highlights strategic adaptations but also points to competitive challenges and retention issues. Without a market cap, the stock's sensitivity is uncertain, but the overall sentiment leans towards a neutral impact on the stock price.
EHTH Slides
EHTH Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
